Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China

doi:10.3748/wjg.v32.i8.115291

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 8

This Article

(45)

(47)

(1)

(0)

(1)

(1066)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Feb 28, 2026; 32(8): 115291
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.115291

Full Size Figure Download Figure

Figure 1 Treatment sequence and model structure for moderate to severe Crohn’s disease. ADA: Adalimumab; IFX: Infliximab; UST: Ustekinumab; VDZ: Vedolizumab.

Citation: Wu Y, Tao LB, Liu C, Wang FX, Yan Y, Sun S. Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China. World J Gastroenterol 2026; 32(8): 115291
URL: https://www.wjgnet.com/1007-9327/full/v32/i8/115291.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i8.115291

Wu Y, Tao LB, Liu C, Wang FX, Yan Y, Sun S. Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China. World J Gastroenterol 2026; 32(8): 115291 [PMID: 41809880 DOI: 10.3748/wjg.v32.i8.115291]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.